Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he’s asked regarding his study on the use of elacestrant (RAD1901) for ER+ advanced breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer
Advertisement